Abstract

The present disclosure relates, inter alia, to therapeutic alkaline phosphatases for the treatment of liver fibrosis.

IPC Classes  ?

• A61K 38/46 - Hydrolases (3)
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

Modified immune cells are provided, the modified immune cells expressing a heterologous polynucleotide comprising a nucleotide sequence encoding a function (e.g., at least one of persistence, proliferation, or cytotoxicity) booster, e.g., an apoptosis inhibitor. In one aspect, the modified T cells further comprise a chimeric antigen receptor. Methods, kits, and components for making and using the modified immune cells are also provided.

IPC Classes  ?

• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• C07K 14/725 - T-cell receptors
• A61P 35/00 - Antineoplastic agents

Abstract

A method of preventing or treating COVID infection in a subject includes selecting two or more COVED CTL epitopes from a Coronavirus proteome that have a network score that meets a threshold value. An effective amount of a T cell immunogen composition and a pharmaceutically acceptable carrier is administered to the subject. The T cell immunogen composition includes the two or more selected Coronavirus CTL epitopes.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• A61P 31/14 - Antivirals for RNA viruses
• C12N 15/86 - Viral vectors
• A61K 9/51 - Nanocapsules

Abstract

Antibody derivatives that have diminished effector function in the initial state owing to the presence of one or more disabling moieties that substantially prevent engagement of the antibody regions responsible for interaction with humoral and cellular immune system effector molecules, and methods of use thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/46 - Hybrid immunoglobulins
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes

Abstract

Disclosed are methods of identifying a cross-modal feature from two or more spatially resolved data sets, the method including: (a) registering the two or more spatially resolved data sets to produce an aligned feature image including the spatially aligned two or more spatially resolved data sets; and (b) extracting the cross-modal feature from the aligned feature image.

IPC Classes  ?

• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• G06T 7/33 - Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods
• G06V 10/762 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using clustering, e.g. of similar faces in social networks
• G06T 7/00 - Image analysis

Abstract

Methods for predicting response to immunotherapy and selecting immunotherapy for treating cancer, e.g., cancer of epithelial origin, in a subject.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Described are antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and/or myeloid-derived suppressor cells (MDSCs), to expand T effector cell populations or function, and to reduce the proliferation of, or directly kill, tumor cells, such as tumor cells that express TNFR2 antigen. The polypeptides, such as antibodies and antigen-binding fragments thereof, are TNFR2 antagonists, such as dominant TNFR2 antagonists. The polypeptides can be used to suppress the T-reg- or MDSC-mediated deactivation of tumor reactive T lymphocytes, expand populations of tumor-reactive cytotoxic T cells, and/or to directly kill TNFR2+ tumor cells. The antagonistic TNFR2 polypeptides described herein can be used to treat a wide variety of cancers and infectious diseases.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Compositions and methods that can increase or stimulate hair growth, as well as novel chemicals that affect hair growth and hair loss.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• C07C 49/457 - Saturated compounds containing a keto group being part of a ring containing halogen
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/047 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

As described below, the present invention features compositions, panels of biomarkers, and methods for characterizing chronic lymphocytic leukemia (CLL) for prognosis and selection of a subject for a treatment and/or inclusion in a clinical trial.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]

Abstract

The disclosure provides compositions comprising an inhibitory nucleic acid targeting IncExACTI, and methods of use thereof to improve cardiac function in a subject in need thereof. Specifically, the disclosure provides a cardiac long noncoding RNA (IncRNA), referred as IncExACT 1 (SEQ ID NO: 1), and inhibitory nucleic acids targeting IncExACT 1 for reducing expression of IncExACT 1 and/or Dachsous cadherin-related 2 (DCHS2) in a cell, e.g., a cell in a subject for improving cardiac function in a subject, wherein the subject has pathological cardiac hypertrophy and/or heart failure.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/86 - Viral vectors
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

The present application provides methods of functionalizing an organ or tissue of a mammal by administering a nutrient (e.g., peracetylated N-azido galactosamine Ac4GalNAz) to the mammal or by culturing an organ or tissue in a bioreactor containing such nutrient. The present application also provides methods of selectively functionalizing extracellular matrix (ECM) of an organ or tissue of a mammal by administering a nutrient (e.g., peracetylated N-azido galactosamine Ac4GalNAz) to the mammal. In some aspects, the present application provides a decellularized scaffold of a mammalian organ or tissue comprising an extracellular matrix, wherein the extracellular matrix of the decellularized scaffold is functionalized with a chemical group that is reactive in a bioorthogonal chemical reaction, such as an azide chemical group. The present application also provides biological prosthetic mesh and mammalian organs and tissues for transplantation prepared according to the methods of the application.

IPC Classes  ?

• C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
• A61L 27/38 - Animal cells
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• C12N 5/07 - Animal cells or tissues
• A61K 31/655 - Azo (—N=N—), diazo (=N2), azoxy (N—O—N or N(=O)—N), azido (—N3) or diazoamino (—N=N—N) compounds
• A61K 35/22 - Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
• A61K 35/34 - Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
• A61K 35/36 - Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
• A61K 35/407 - Liver; Hepatocytes
• A61K 35/42 - Respiratory system, e.g. lungs, bronchi or lung cells
• A61K 35/44 - Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof

Abstract

The invention features methods that are useful for treatment of a patient at increased risk for infection and for selecting a patient for treatment for an infection. In various embodiments, the infection is coronavirus disease 2019 (COVID-19), sepsis, or other respiratory infections.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis

Abstract

Systems, methods, and apparatus for differential phase contrast microscopy by transobjective differential epi-detection of forward scattered light are provided. In some embodiments, a microscope objective comprises: a housing with mounting threads at a second end; optical components defining an optical axis, comprising: an objective lens mounted at a first end, configured to collect light from a sample placed in a field of view, the plurality of optical components create a pupil plane at a first distance along the optical axis at which rays having the same angle of incidence on the objective lens converge at the same radial distance from the optical axis; a photodetector within the housing offset from the optical axis at a second distance along the optical axis; and another photodetector within the housing at second distance along the optical axis and offset from the optical axis in the opposite direction from the first photodetector.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
• G02B 21/14 - Condensers affording illumination for phase-contrast observation
• G02B 21/00 - Microscopes
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
• G01N 15/14 - Electro-optical investigation
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G02B 21/08 - Condensers
• G02B 26/12 - Scanning systems using multifaceted mirrors
• G02B 21/36 - Microscopes arranged for photographic purposes or projection purposes

Abstract

Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and treatment with one or more proton motive force (PMF) stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
• A01N 37/06 - Unsaturated carboxylic acids or thio-analogues thereof; Derivatives thereof
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61K 31/191 - Acyclic acids having two or more hydroxy groups, e.g. gluconic acid
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

An apparatus for obtaining image data and functional data from a biological sample, the apparatus including: an interferometer configured to acquire interferometric information at a plurality of time points along an imaging plane for which at least one axis of the plane is at least partially along a depth or axial dimension that is based on radiations provided from a reference interfered with by the biological sample; and a processor configured to receive the interferometric information from the interferometer and configured to: process the interferometric information to generate an image of the biological sample along the imaging plane; determine frequency information based on the plurality of time points of the interferometric information, the frequency information reflecting temporal modulations induced by dynamic functions of the biological sample; generate a spatial map of the frequency information, and the spatial map of the frequency information indicating the dynamic functions of the biological sample.

IPC Classes  ?

• G01N 21/47 - Scattering, i.e. diffuse reflection

Abstract

Cosmetic method and apparatus are provided that can provide cooling and/or freezing of skin tissue proximal to the skin surface to generate an appearance of lightening or reduced pigmentation in the skin. The skin can be cooled to a temperature of less than about -5° C. for a duration of about one minute or less, using a cooled surface that is at least 3 cm in width. A cooling arrangement can be provided to provide controlled heat removal from the skin tissue being treated. A sensor can optionally be provided to detect freezing of tissue proximal to the cooled surface.

IPC Classes  ?

• A61F 7/00 - Heating or cooling appliances for medical or therapeutic treatment of the human body
• A61F 7/02 - Compresses or poultices for effecting heating or cooling
• A61B 18/02 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques

Abstract

Provided herein are compounds that are able to bind metal ions (e.g., free metal ions or metal ions bound to low affinity ligands) in a sample or subject. Also provided herein are methods of using the compounds for chelating metal ions and for the treatment of diseases associated with abnormal levels of metal ions. Methods of preparing the compounds and pharmaceutical compositions are also provided.

IPC Classes  ?

• C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
• C09B 69/10 - Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds

Abstract

The present invention provides for single-molecule profiling of combinatorial protein modifications and single-molecule profiling of combinatorial protein modifications combined with single-molecule sequencing of protein/nucleic acids complexes. High-throughput single-molecule imaging was applied to decode combinatorial modifications on millions of individual nucleosomes from pluripotent stem cells and lineage-committed cells. Applicants identified bivalent nucleosomes with concomitant repressive and activating marks, as well as other combinatorial modification states whose prevalence varies with developmental potency. Applying genetic and chemical perturbations of chromatin enzymes show a preferential affect on nucleosomes harboring specific modification states. The present invention also combines this proteomic platform with single-molecule DNA sequencing technology to simultaneously determine the modification states and genomic positions of individual nucleosomes. This novel single-molecule technology can be used to address fundamental questions in chromatin biology and epigenetic regulation leading to novel therapeutics and diagnostics.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Abstract

Hydrogel beads having tunable rates of loading and unloading of cryoprotective agents are provided herein. Such hydrogel beads can be dispersed throughout a cell suspension to enable loading and unloading of cryoprotective agents from cells in a gradual and distributed manner that protects the cells from osmotic damage. Lymphocyte viability after cryopreservation is significantly greater when cryoprotective agents are loaded and unloaded using hydrogel beads compared to conventional media exchange methods.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

Abstract

A point-of-care device for detecting nucleic acid is disclosed. The point-of-care device for detecting nucleic acid according to an exemplary embodiment of the present invention includes a rotating body in which a plurality of test tubes containing a sample mixed with heat-generating particles that generate heat when irradiated with light beams are radially coupled around a rotation shaft; a first actuator for rotating the rotating body such that the test tube rotates about the rotation shaft; and an irradiation module for irradiating the light beams to an irradiated area which is set on a rotation path of the test tube, wherein the rotation path includes a non-irradiated area to which the light beams are not irradiated, and wherein the test tube proceeds through the irradiated area and the non-irradiated area on the rotation path according to the rotation of the rotating body.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• B01L 7/00 - Heating or cooling apparatus; Heat insulating devices
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage

Abstract

The present disclosure is in the field of diagnostics and therapeutics for Alzheimer's Disease.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• C12N 15/86 - Viral vectors
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• C12N 15/864 - Parvoviral vectors

Abstract

A cellular coding construct uniquely codes a cellular entity and includes a laser particle and a structurally coded oligonucleotide. The structurally coded oligonucleotide and the laser particle have a physical association with each other and are configured for physical association with the cellular entity and also configured for distinctive identification of the cellular entity.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Abstract

Systems and methods are provided for evaluating a stability of a joint within the foot and ankle complex of a subject. The subject is instructed to assume a position in which the joint is bearing weight, and a three-dimensional medical image of the joint comprising a sequence of two-dimensional image slices is captured at a scanner. The sequence of two-dimensional image slices is provided to a predictive model, comprising an artificial neural network having at least one convolutional layer. A clinical parameter representing the stability of the joint at the predictive model is determined from at least the sequence of two-dimensional image slices.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
• G06T 7/00 - Image analysis
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G06N 5/022 - Knowledge engineering; Knowledge acquisition

Abstract

Aspects of the present disclosure provide devices and methods for rapid, quantitative, on-site detection of controlled substances. Devices include a sample processing module and a sensor cartridge, and optionally a detection cradle.

IPC Classes  ?

• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics
• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

Described herein are compositions and methods for treating cancer in a subject. Using the compositions and methods of the disclosure, a subject may be administered (i) an inhibitor and/or an overrider and (ii) a chemotherapeutic.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61P 35/00 - Antineoplastic agents
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 31/502 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/47 - Quinolines; Isoquinolines
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

Abstract

A sensor system includes a probe, and a photon source configured to direct photons at the probe. The probe can emit light in response to receiving photons. The sensor system can include a photodetector configured to detect the light emitted from the probe, and a configured to cause the photon source to emit photons according to a first time-varying intensity profile having a first frequency. The controller can be configured to receive optical data from the photodetector based on the interaction between the light emitted from the probe and the photodetector. The optical data can include a second time-varying intensity profile having a second frequency. The second frequency can be substantially the same as the first frequency. The controller can be configured to determine a difference in phase between the first time-varying intensity profile and the second time-varying intensity profile, and generate a report based on the difference in phase.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

Systems and devices for compressing a 5th metatarsal fracture of the foot are provided. A bone fixation device is provided that includes an opening for receiving a bone screw. The device also includes at least one hook sized and configured to be placed at the base of the 5th metatarsal bone of the foot. Drill guides and bone tap guides are also provided that include at least one hook sized and configured to placed at the base of the 5th metatarsal bone of the foot.

IPC Classes  ?

• A61B 17/86 - Pins or screws
• A61B 17/72 - Intramedullary devices
• A61B 17/17 - Guides for drills

Abstract

Described herein are methods and compositions for treating cancer, fibrosis, and inflammation, and reducing risk of developing cancer, fibrosis, and inflammation, using small molecule inhibitors of IL-33, i.e., pitavastatin calcium, tropisetron, ammonium glycyrrhizinate, ticagrelor, and cetrimonium bromide.

IPC Classes  ?

• A61K 31/47 - Quinolines; Isoquinolines
• A61K 31/46 - 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - Ointments; Bases therefor

Abstract

A guiding apparatus, system, method, and forceps device for facilitating placement of sutures in a surgical procedure. The apparatus including a shaft portion having a non-circular aperture extending laterally therethrough and a blade portion having a shank extending at an angle from the shaft portion and a blade having a blade aperture extending from the shank. The system includes a plurality of the apparatuses held substantially parallel by an elongated rod through the apertures of the shafts. The blade apertures guide the at least one suture to a desired location to pierce through a target body tissue.

IPC Classes  ?

• A61B 17/04 - Surgical instruments, devices or methods, e.g. tourniquets for closing wounds, or holding wounds closed, e.g. surgical staples; Accessories for use therewith for suturing wounds; Holders or packages for needles or suture materials
• A61B 17/28 - Surgical forceps

Abstract

Systems and methods are provided for determining a clinical parameter via evaluation of sequential medical images. A sequence of at least three medical images for a patient are captured at a scanner. A set of at least two difference images are generated from the sequence of at least three medical images. Each difference image represents a difference in content between two adjacent images in the sequence of at least three medical images. The set of at least two difference images are provided to a predictive model. The predictive model includes an artificial neural network having at least one convolutional layer. A clinical parameter for the patient is determined at the predictive model from at least the set of at least two difference images.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 5/50 - Image enhancement or restoration by the use of more than one image, e.g. averaging, subtraction
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance

Abstract

A method for identifying plaque erosion in a vessel. The method includes: obtaining, using a processor, a sequence of images of the vessel; extracting, using the processor, one or more image features from the sequence of images using a convolutional neural network model; contextually classifying, using the processor, the one or more extracted image features using a cascaded self-attention trained model; and generating, using the processor, one or more diagnostic labels associated with the sequence of images based on contextually classifying the one or more extracted image features, where the one or more diagnostic labels may include an indication of a presence of plaque erosion or an absence of plaque erosion.

IPC Classes  ?

• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
• A61B 6/03 - Computerised tomographs
• G06N 3/084 - Backpropagation, e.g. using gradient descent
• G06T 7/00 - Image analysis
• G06N 3/0499 - Feedforward networks
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

The invention related to therapeutic polymeric materials and medical implants containing additives and/or analgesic agents. The invention also relates to methods of making therapeutic polymeric materials and medical implants containing additives and/or analgesic agents. Methods of spatially controlling additive concentrations and release as well as polymeric material morphology are also provided.

IPC Classes  ?

• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/34 - Macromolecular materials
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers

Abstract

Reusable network of spatially-multiplexed microfluidic channels each including an inlet, an outlet, and a cuvette in-between. Individual channels may operationally share a main or common output channel defining the network output and optionally leading to a disposable storage volume. Alternatively, multiple channels are structured to individually lead to the storage volume. An individual cuvette is dimensioned to substantially prevent the formation of air-bubbles during the fluid sample flow through the cuvette and, therefore, to be fully filled and fully emptied. The overall channel network is configured to spatially lock the fluidic sample by pressing such sample with a second fluid against a closed to substantially immobilize it to prevent drifting due to the change in ambient conditions during the measurement. Thereafter, the fluidic sample is flushed through the now-opened valve with continually-applied pressure of the second fluid. System and method for photometric measurements of multiple fluid samples employing such network of channels.

IPC Classes  ?

• G01N 21/03 - Cuvette constructions
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• G01N 21/11 - Filling or emptying of cuvettes
• G01N 21/25 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands

Abstract

The invention is directed to a composition comprising cromolyn sodium and ibuprofen, wherein the cromolyn sodium is micronized and the cromolyn sodium and ibuprofen are present in a weight ratio of 1:1-2. In one embodiment, the ibuprofen is passed through a sieve, such as a 300 μm sieve and to methods of making the same.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 9/16 - Agglomerates; Granulates; Microbeadlets

Abstract

Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and packs and kits comprising cromolyn are described.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61M 16/14 - Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
• A61M 15/00 - Inhalators
• A61P 11/06 - Antiasthmatics

Abstract

Described herein are methods for producing and utilizing an alternative signal 1 domain to construct an optimally signaling CAR. Alternative signal 1 domains of the present technology are based on alternatives to CD3ζ, including mutated ITAMs from CD3ζ (which contains 3 IT AM motifs), truncations of CD3ζ, and alternative splice variants known as CD3s, CD3 theta, and artificial constructs engineered to express fusions between CD3s or CD30 and CD3ζ. CAR polypeptides comprising alternative signal 1 domains are utilized to engineer CAR T cells. Further, this technology related to methods of treating cancer by administering to a subject in need thereof CAR T cells comprising alternative signal 1 domains.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 35/00 - Antineoplastic agents
• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

Abstract

Systems and methods ate provided that may facilitate the self-administration of an odor-based, or smell test. The test may include like patient performing an odor intensity test, odor identity test, and/or odor discrimination test using an odor proctor or testing kit. The testing kit can include the odor proctor and a test guide. The test guide may be used with the odor proctor to perform various smell test(s). The test guide may be realized in software that is readily available via a personal computing device.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu

Abstract

Exemplary apparatus and method can be provided. For example, using at least one light source first arrangement, it is possible to provide pulses of light to at least one portion of a biological structure. At least one detector second arrangement can be used to detect images from the portion(s) based on the pulses, and provide data based on the detection. With at least one configuration, it is possible prevent and/or reduce a movement of the apparatus within at least one anatomical body (i) is a particular surface of the apparatus, (ii) covers at least one portion of the surface, and/or (iii) extends from the surface. In addition or alternatively, with at least one computer third arrangement, it is possible to receive the data, and control a timing of at least one of activation or deactivation of at least one portion of the first arrangement based on the data.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
• A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

In accordance with some non-limiting examples of the disclosed subject matter, an ingestible system configured to acquire physiological information from an interior of a subject is provided, comprising a substrate and at least one physiological sensor. The at least one physiological sensor can be coupled to the substrate and configured to capture physiological data from at least one of an internal area or an orientation in a digestive tract of the subject. The system can include a controller coupled to the substrate and configured to receive the physiological data and prepare the physiological data for one of transmission from the subject or analysis of the physiological data. The substrate, including the at least one physiological sensor and the controller coupled thereto can be configured to self-orient within the digestive tract of the subject, during ingestion of the system by the subject. The substrate can additionally orient the at least one physiological sensor in the at least one of the internal area or the orientation in the digestive tract of the subject.

IPC Classes  ?

• A61B 5/285 - Endotracheal, oesophageal or gastric probes
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• A61B 5/0537 - Measuring body composition by impedance, e.g. tissue hydration or fat content
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/361 - Detecting fibrillation
• A61B 5/07 - Endoradiosondes

Abstract

Described herein are systems, methods, and compositions for the precise editing of DNA sequence(s) at specific loci to alter expression of target gene products at the pre-transcriptional or post-transcriptional level in a durable fashion, termed Stable and Heritable Alteration by Precision Editing (SHAPE). The SHAPE platform utilizes genetic modifiers (e.g., nucleases, (CRISPR guided) transposases, recombinases, base editors, and prime editors) to install specific sequence motifs at target sequences through precision genome engineering.

IPC Classes  ?

• G16B 20/30 - Detection of binding sites or motifs
• G16B 30/10 - Sequence alignment; Homology search
• C12N 9/22 - Ribonucleases
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

Described herein are methods of determining segregation dynamics of mitochondrial DNA herein. Also described herein are methods of diagnosing, prognosing, and/or monitoring a mitochondrial disease.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Abstract

The present disclosure relates to compositions and methods for nucleic acid sequencing, and specifically, at least in certain aspects, provides methods and compositions for enhancing the efficacy, throughput and/or yield of known long-range sequencing platforms, by providing chimeric arrays of input sequences. Such arrays of component nucleic acid sequence elements can be prepared via methods that minimize introduction of bias. The application of the current methods to obtain isoform sequencing information, e.g., from patient samples is specifically also provided, as are methods for mitochondrial lineage tracing that employ the instant chimeric amplicon sequencing processes. Methods and systems for array nucleic acid sequence processing and interpretation are also provided.

IPC Classes  ?

• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]

Abstract

A computer-implemented method for diagnosing a medical condition of a patient is provided. The method can include causing, using one or more processors, an excitation source to emit an excitation light towards a region of interest of an artery, receiving, using the one or more processors and a detector, imaging data of the region of interest of the artery, generating, using the one or more processors and the imaging data, an image of the region of interest, determining, using the one or more processors, a risk region of an atheromatous plaque, based on the imaging data, and determining, using the one or more processors, that the patient has a severe case of an atheromatous plaque, based on the determined risk region of the atheromatous plaque.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

The present disclosure provides a method of treating cancer in a subject in need thereof comprising administering a checkpoint inhibitor to the subject, and administering a MALT-1 inhibitor according to an intermittent dosage regimen.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

Systems/techniques that facilitate automated training of machine learning classification for patient missed care opportunities or late arrivals are provided. In various embodiments, a system can access a set of annotated data candidates defined by two or more feature categories. In various aspects, the system can train a machine learning classifier on the set of annotated data candidates, thereby causing internal parameters of the machine learning classifier to become iteratively updated. In various instances, the system rank the two or more feature categories in order of classification importance, based on the iteratively updated internal parameters of the machine learning classifier. In various cases, the system can perform one or more electronic actions based on the two or more feature categories being ranked in order of classification importance.

IPC Classes  ?

• G06N 20/00 - Machine learning
• G06Q 10/10 - Office automation; Time management

Abstract

The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein. The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/ or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.

IPC Classes  ?

• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans

Abstract

The present disclosure relates to a pharmaceutical composition, such as a dry powder inhalation formulation or an injectable formulation, comprising a mixture of an antiviral agent and a mast cell stabilizer. The present disclosure relates to a codrug comprising a residue of an antiviral agent covalently bonded via a labile bond to a residue of a compound of Formula (I) or Formula (II). The present disclosure further relates to a method of administering an antiviral agent and a Formula I/II compound, a pharmaceutical composition, or a codrug to treat coronavirus infection and/or associated inflammation.

IPC Classes  ?

• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/664 - Amides of phosphorus acids
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Methods, systems, compositions and strategies for the use of ARMM-mediated delivery of molecules (e.g., biological molecules, small molecules, proteins, and nucleic acids (e.g., DNA, RNA), DNA plasmids shRNA, mRNA) to cells of the nervous system (e.g., central nervous system and peripheral nervous system).

IPC Classes  ?

• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• A61K 9/50 - Microcapsules
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

Disclosed are bispecific compounds (degraders) that target α-synuclein protein for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat neurodegenerative diseases.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

Enhanced virus-like particles (eVLPs), comprising a membrane comprising a phospholipid bilayer with one or more virally-derived glycoproteins on the external side; and a cargo disposed in the core of the eVLP on the inside of the membrane, wherein the eVLP does not comprise an exogenous gag/pol protein, and methods of use thereof for delivery of the cargo to cells.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof

Abstract

Disclosed herein are methods, compositions, systems, and kits related to functional testing of soluble polypeptides in a single-cell format.

IPC Classes  ?

• G01N 33/566 - Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagent
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

An infusion apparatus includes a housing and a chamber configured to be connected to the housing. The apparatus further includes a weight sensor coupled to a load connector connected to the housing and an optical sensor disposed in the housing. The weight sensor is configured to generate a first signal based on a measured weight of the fluid container attached to the housing in a weight-bearing configuration. The optical sensor is configured to generate a second signal based on detecting drops of the fluid traversing the chamber. The apparatus also includes a flow control mechanism to control a flow rate of the fluid into an outlet channel. The apparatus includes one or more processing devices configured to perform operations including transmitting a control signal to the flow control mechanism to adjust the flow rate.

IPC Classes  ?

• A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
• G01G 17/06 - Apparatus for, or methods of, weighing material of special form or property for weighing fluids, e.g. gases, pastes having means for controlling the supply or discharge
• A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
• G01F 1/72 - Devices for measuring pulsing fluid flows
• G01F 1/661 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by measuring frequency, phase shift or propagation time of electromagnetic or other waves, e.g. using ultrasonic flowmeters using light
• G01N 15/14 - Electro-optical investigation
• G01G 19/18 - Weighing apparatus or methods adapted for special purposes not provided for in groups for weighing suspended loads having electrical weight-sensitive devices
• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic

Abstract

A system for integrated electric field simulation and neuronavigation includes a neuronavigation system configured to track an electromagnetic coil used for neuromodulation of a brain of a subject and an electric field simulation neural network coupled to the neuronavigation system. The electric field simulation neural network is configured to generate a simulated electric field for a region of interest based at least on a coil position and orientation, a magnetic field profile of the electromagnetic coil, and multimodal neuroimaging data associated with the subject. The system further includes a display coupled to the electric field simulation neural network and configured to display the simulated electric field. The region of interest can be the brain of the subject and the electromagnetic coil can be a transcranial magnetic stimulation (TMS) coil.

IPC Classes  ?

• A61N 2/00 - Magnetotherapy
• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets

Abstract

A system may transform sensor data from a sensor domain to an image domain using data-driven manifold learning techniques which may, for example, be implemented using neural networks. The sensor data may be generated by an image sensor, which may be part of an imaging system. Fully connected layers of a neural network in the system may be applied to the sensor data to apply an activation function to the sensor data. The activation function may be a hyperbolic tangent activation function. Convolutional layers may then be applied that convolve the output of the fully connected layers for high level feature extraction. An output layer may be applied to the output of the convolutional layers to deconvolve the output and produce image data in the image domain.

IPC Classes  ?

• G06T 11/00 - 2D [Two Dimensional] image generation

Abstract

The disclosure relates to methods for treating a subject suffering from a burn injury or associated complications by administering to the subject an effective amount of an aromatic-cationic peptide. For example, a burn injury may be associated with distant pathophysiological effects, such as hypermetabolism, skeletal muscle dysfunction, and organ damage. The disclosure also relates to methods for protecting a subject from a burn injury by administering an effective amount of an aromatic-cationic peptide to a subject at risk of a burn injury.

IPC Classes  ?

• A61K 38/07 - Tetrapeptides
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The disclosure provides methods of assessing a subject's risk of ascending thoracic aortic aneurysm or descending thoracic aortic aneurysm by detecting one or more single nucleotide polymorphisms (SNP) in one or more specific genes. The disclosure also provides methods of calculating a polygenic score to assess a subjects risk. Such methods may be used, for example, to identify asymptomatic subjects at risk for aneurysm.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Systems and methods for generating and delivering nitric oxide are provided. In one aspect, a nitric oxide generator includes an inlet arranged to receive a gas including nitrogen and oxygen, an outlet, a pair of electrodes arranged downstream of the inlet and configured to generate nitric oxide from the gas, a pressure regulator configured to selectively adjust a pressure of the gas surrounding the electrodes, an accumulator in communication with the pressure regulator, a nitric oxide sensor arranged to measure a concentration of nitric oxide at the outlet, and a controller in communication with the pair of electrodes, the pressure regulator, and the nitric oxide sensor. The controller is configured to selectively instruct the pressure regulator to adjust the pressure of the gas surrounding the electrodes in response to the concentration of nitric oxide measured at the outlet by the nitric oxide sensor.

IPC Classes  ?

• A61M 16/12 - Preparation of respiratory gases or vapours by mixing different gases
• A61M 16/10 - Preparation of respiratory gases or vapours
• A61M 16/20 - Valves specially adapted to medical respiratory devices

Abstract

A method of forming a tissue or an organ, including: disposing, in a support medium in a gel state, a composition comprising a live biologic; changing a state of the support medium from the gel state to a solid state; and supporting, in the support medium at the solid state, the live biologic in the composition.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/26 - Inoculator or sampler
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• B33Y 80/00 - Products made by additive manufacturing

Abstract

The present disclosure relates to compositions and methods for single-cell nucleic acid sequencing, and specifically provides for pre-amplifying target nucleic acids in a manner that allows for more proportionate detection of all target nucleic acids, including low prevalence/abundance RNAs, from individual cells. The disclosure also provides for application of a series of barcoding steps to associate cell-specific identifiers (IDs) to the targeted nucleotide sequences, and ultimately provides for increased throughput capacity and greater accuracy of single-cell nucleic acid sequencing. Certain aspects of the present disclosure also provide for improved quantitative detection of nucleic acid sequence barcodes, which in embodiments allows for highly sensitive quantitative detection of barcoded antibody levels and/or highly sensitive quantitative detection of barcoded antibody-bound protein levels (e.g., where specific antibodies are labeled with a barcoded oligonucleotide that is specific to each barcoded antibody's target. In such approaches, the oligonucleotide barcode can serve as a target nucleic acid sequence for the capture probes of the instant disclosure. Compositions, methods and kits related to specific combinations of capture probes are also provided.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

Methods of making consolidated blend(s) of polymeric material(s) with one or more therapeutic agents (such as an antibiotic) are provided, wherein the method comprises the steps of providing a polymeric material, blending the polymeric material with one or more therapeutic agent(s), pelletizing the blended polymeric material, environmentally treating by various approaches the pelletized polymeric material, and consolidating the environmentally treated pellet. Products made by the methods and uses of the products also are provided.

IPC Classes  ?

• A61K 9/16 - Agglomerates; Granulates; Microbeadlets
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61J 3/00 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
• B29B 9/16 - Auxiliary treatment of granules
• B29B 9/10 - Making granules by moulding the material, i.e. treating it in the molten state

Abstract

The present invention relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to four biotinylated components, and further wherein at least two of the four biotinylated components are not identical.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• C07K 14/35 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Methods and compositions for enhancing Wnt signaling pathway activities in a tissue of a subject have been developed for the treatment of cancer, in particular cancers with one or more mutations in the APC (adenomatous polyposis coli) gene. Preferably, the amount of the compositions for enhancing Wnt signaling does not reduce or inhibit proliferation or viability of normal healthy cells in the subject. In some embodiments, pharmaceutical compositions including an effective amount of one or more GSK-3 inhibitors are administered to reduce cancer cell proliferation or viability in a subject. A preferred GSK-3 inhibitor is LY2090314 encapsulated within, or associated with nanoparticles. Dosage forms of LY2090314 encapsulated within, or associated with nanoparticles for administration are also described.

IPC Classes  ?

• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 14/475 - Growth factors; Growth regulators
• A61P 35/00 - Antineoplastic agents
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

X-ray absorption of breast cancers and surrounding healthy tissue can be very similar, a situation that sometimes leads to missed cancers or false-positive diagnoses. To increase the accuracy of tomosynthesis and cancer diagnosis, dynamic X-ray elastography using a novel pulsed X-ray source synchronized to shear waves generated in a sample is described in the present disclosure. This imaging modality provides both absorption and mechanical properties of the imaged sample. A vibration source is used to vibrate the sample while a synchronously pulsed cold cathode X-ray source images the mechanical deformation. The generated stroboscopic images are further used to derive stiffness maps of the sample in addition to the conventional X-ray image.

IPC Classes  ?

• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment

Abstract

Exemplary embodiments of an apparatus can be provided for obtaining portions or samples of tissue from a target region of a biological tissue. One or more needles can be provided that have a small internal diameter, e.g., about 1 mm or less, and the needles can be configured to extract the tissue portions when the needles are inserted into and withdrawn from the tissue. Windows and/or markings can be provided on the wall of the needles to facilitate access to the sample. The needles can be provided in an enclosure, and an actuator can be provided to direct the needles into the tissue and/or withdraw them. A plurality of tissue portions having known relative locations in the target region can be obtained, and extraction of the tissue portions can be well-tolerated by the tissue as compared with conventional punch biopsies or the like.

IPC Classes  ?

• A61B 10/02 - Instruments for taking cell samples or for biopsy
• A61B 90/30 - Devices for illuminating a surgical field, the devices having an interrelation with other surgical devices or with a surgical procedure
• A61B 90/92 - Identification means for patients or instruments, e.g. tags coded with colour
• A61B 90/94 - Identification means for patients or instruments, e.g. tags coded with symbols, e.g. text

Abstract

Described herein are methods of treating a subject who has an infection with a coronavirus, e.g., SARS-COV-2, and for reducing risk of infection or severity of infection, with a coronavirus, e.g., SARS-COV-2, the method comprising administering an effective amount of a benzimidazole.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/42 - Oxazoles
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Abstract

The present invention relates to systems and methods for screening natural products such as secondary metabolites produced by engineered microbial strains.

IPC Classes  ?

• A01H 3/04 - Processes for modifying phenotypes by treatment with chemicals
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• C12N 1/12 - Unicellular algae; Culture media therefor
• C12N 1/14 - Fungi ; Culture media therefor
• C12N 1/16 - Yeasts; Culture media therefor
• C12N 1/20 - Bacteria; Culture media therefor
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

A radiation detection device includes a sensor having a first electrode and a second electrode. The first and second electrode each defines a plurality of fingers comprising a nanotube material, and the fingers of each electrode are interdigitated with one another. A voltage source may be configured to apply a voltage across the first and second electrodes. A chamber contains the sensor with a gas, one or more walls of the chamber enabling passage of radiation external to the chamber. A detection circuit detects radiation within the chamber based on a change in current across the first and second electrodes resulting from ionization of the gas by the radiation.

IPC Classes  ?

• G01T 1/185 - Measuring radiation intensity with ionisation-chamber arrangements

Abstract

Methods for the use of glutathione trisulfide (GSSSG) in neuroprotection, e.g., in neurodegenerative diseases and to reduce the risk of ischemic injury. The methods can be used, e.g., to reduce risk of injury to brain, spinal cord, and peripheral nerves from ischemia or low blood flow states possibly caused by surgery, trauma, and other conditions that decrease/impair blood flow and or oxygen delivery to the nervous system.

IPC Classes  ?

• A61K 38/06 - Tripeptides
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Described are agonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to stimulate the proliferation of regulatory T cells (Treg cells) and/or myeloid-derived suppressor cells (MDSCs), as well as to inhibit the function of, reduce the proliferation of, and/or directly kill, T effector cells, such as CD8+ T effector cells. The polypeptides, such as antibodies and antigen-binding fragments thereof, of the disclosure can be used, for example, to suppress autoimmunity and inflammation, as well as to promote the protection, healing, preservation, and/or regeneration of a wide variety of tissues and organs, such as tissues and organs containing TNFR2+ cells.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Methods and devices for evaluating coagulation are described, including methods and devices for detecting an anticoagulant agent or a coagulation abnormality. In various embodiments, the methods and devices of the invention measure coagulation of a sample in response to a gradient of one or more coagulation factors. These responses can be evaluated to accurately profile coagulation impairments of the sample, including the presence of anticoagulant medication. In various embodiments, the invention provides point-of-care or bedside testing with a convenient, microfluidic device that can be used by minimally trained personnel.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• G01N 33/86 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)

Abstract

The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, i.e. aneuploidy. In addition, the present invention provides methods to determine when there are insufficient fetal cells for a determination and report a non-informative case. The present invention involves quantifying regions of genomic DNA from a mixed sample. More particularly the invention involves quantifying DNA polymorphisms from the mixed sample.

IPC Classes  ?

• G01N 1/30 - Staining; Impregnating
• G16B 20/10 - Ploidy or copy number detection
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Described herein are chimeric antigen receptors (CARs) targeting CD37, as well as related molecules and methods.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants

Abstract

Systems, methods, and device can be used to detect target extracellular vesicles (“EVs”). One example of a method includes obtaining a nano-plasmonic array including nanostructures configured to amplify one or more specific wavelengths of electromagnetic radiation, flowing a liquid sample over the nano-plasmonic array, optionally labeling target EVs captured on the nano-plasmonic array with one or more reporter groups, projecting electromagnetic radiation onto the labeled target EVs captured on the nano-plasmonic array, and capturing an image of the target EVs by receiving electromagnetic radiation emitted, scattered, or reflected by the EVs or by reporter groups on the labeled target EVs.

IPC Classes  ?

• G01N 15/14 - Electro-optical investigation

Abstract

A method for reconstructing a motion-corrected magnetic resonance image of a subject includes providing k-space magnetic resonance data including a plurality of shots, wherein each shot corresponds to an individual motion state of the subject. The method further includes providing motion parameters related to each motion state, determining redundancies across the motion states of the plurality of shots based on the motion parameters, compressing the plurality of motion states based on the determined redundancies across the motion states, and reconstructing the magnetic resonance image from the k-space magnetic resonance data based on the compressed plurality of motion states.

IPC Classes  ?

• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G01R 33/48 - NMR imaging systems

Abstract

Methods and devices for evaluating coagulation are described, including methods and devices for detecting an anticoagulant agent or a coagulation abnormality. In various embodiments, the methods and devices of the invention measure coagulation of a sample in response to a gradient of one or more coagulation factors. These responses can be evaluated to accurately profile coagulation impairments of the sample, including the presence of anticoagulant medication. In various embodiments, the invention provides point-of-care or bedside testing with a convenient, microfluidic device that can be used by minimally trained personnel.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• G01N 33/86 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)

Abstract

Methods and devices for evaluating coagulation are described, including methods and devices for detecting an anticoagulant agent or a coagulation abnormality. In various embodiments, the methods and devices of the invention measure coagulation of a sample in response to a gradient of one or more coagulation factors. These responses can be evaluated to accurately profile coagulation impairments of the sample, including the presence of anticoagulant medication. In various embodiments, the invention provides point-of-care or bedside testing with a convenient, microfluidic device that can be used by minimally trained personnel.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• G01N 33/86 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)

Abstract

The present disclosure relates to a method of treating one or more inflammation conditions induced by a coronavirus infection in a subject in need thereof, comprising administering a pharmaceutical composition comprising a compound of Formula I or Formula II, wherein R1 is halogen, OH, or —OC(O)C1-5alkyl, R2 and R3 are each independently selected from CO2R4 and CH2OR5; R4 is Li, Na, K, H, C1-5-alkyl, or —CH2CO(C1-5alkyl); and R5 is H or —C(O)(C1-5alkyl), or a pharmaceutically acceptable salt thereof. The present disclosure relates to a method of treating one or more inflammation conditions induced by a coronavirus infection in a subject in need thereof, comprising administering a pharmaceutical composition comprising a compound of Formula I or Formula II, wherein R1 is halogen, OH, or —OC(O)C1-5alkyl, R2 and R3 are each independently selected from CO2R4 and CH2OR5; R4 is Li, Na, K, H, C1-5-alkyl, or —CH2CO(C1-5alkyl); and R5 is H or —C(O)(C1-5alkyl), or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 31/14 - Antivirals for RNA viruses
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The disclosure includes compositions comprising synthetic zinc finger degrons, and their use with non-naturally occurring or engineered programmable nucleases. Compositions specifically targeting the engineered programmable nucleases for control of gene editing outcomes, and compositions, systems and method of use are further detailed.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Abstract

Described are compositions and methods for determining the propensity of a subject with diabetes (e.g., type 1 diabetes) to benefit from treatment with Bacillus Calmette-Guerin (BCG). Using the compositions and methods of the disclosure, a subject with diabetes (e.g., type 1 diabetes) may be identified as likely to respond to BCG therapy on the basis, for example, of a determination that the subject was young (e.g., less than 40 years of age) at the time of onset of the diabetes. Additionally, or alternatively, the subject may be identified as likely to respond to BCG therapy based on a determination that the subject exhibits a reduced rate of glucose uptake, an elevated rate of oxidative phosphorylation, and/or a reduced rate of aerobic glycolysis, for example, as compared to a healthy subject (e.g., a subject without diabetes). The compositions and methods of the disclosure can additionally be used to administer BCG to subjects identified as likely to respond to treatment with a composition comprising BCG.

IPC Classes  ?

• A61K 35/741 - Probiotics
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Described herein are fluorinated derivatives of gabapentin and methods of synthesis and methods of use thereof, e.g., in imaging and therapy.

IPC Classes  ?

• C07C 229/32 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
• C07B 39/00 - Halogenation
• C07C 235/14 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• C07D 209/54 - Spiro-condensed
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• A61K 51/04 - Organic compounds

Abstract

The present invention relates to methods and compositions for treating human papilloma virus (HPV)-associated diseases using an inhibitor of CXCL12 signaling. The invention further relates to methods and compositions for treating immune checkpoint blockade resistant diseases using an inhibitor of CXCL12 signaling. The invention further relates to methods and compositions for enhancing the immune response against an HPV-associated disease using an inhibitor of CXCL12 signaling.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61P 35/00 - Antineoplastic agents
• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• A61K 39/12 - Viral antigens
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Abstract

Disclosed herein are methods for inducing insulin secretion in a glucose-dependent manner and compounds for use in these methods.

IPC Classes  ?

• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
• C07C 235/84 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
• C07D 213/30 - Oxygen atoms
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 237/08 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 495/04 - Ortho-condensed systems

Abstract

Asymmetric, single-channel radio frequency (“RF”) coils are provided for use with portable or other low-field magnetic resonance imaging (“MRI”) systems. In general, the asymmetric, single-channel RF coils make use of asymmetric, optimized winding configurations in order to reduce B1+ inhomogeneities and to reduce signal sensitivity outside of the desired imaging field-of-view (“FOV”).

IPC Classes  ?

• G01R 33/34 - Constructional details, e.g. resonators
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

The disclosure relates to compositions, methods, and kits for treating leukemia, specifically acute myeloid leukemia, in a subject.

IPC Classes  ?

• A61K 31/47 - Quinolines; Isoquinolines
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin

Abstract

Systems and methods for producing nitric oxide (NO) to be used in medical applications are provided. In some embodiments, systems and methods are provided for a NO generator that is capable of generating a desired concentration of NO to be provided to a respiratory system for inhalation by a patient.

IPC Classes  ?

• A61M 16/12 - Preparation of respiratory gases or vapours by mixing different gases
• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
• A61M 16/10 - Preparation of respiratory gases or vapours
• C01B 21/32 - Apparatus
• C01B 21/30 - Preparation by oxidation of nitrogen

Abstract

Instances of a single brain computer interface (BCI) system can be implemented on multiple devices. An active instance can control the associated device. The instances can each communicate with a neural decoding system that can receive neural signals from a user, process the neural signals, and output a command based on the processed neural signals. A device running the active instance of can be in communication with the neural decoding system to receive a command. The device can include a display, a non-transitory memory storing instructions, and a processor to execute the instructions to: run an instance of a control program; and execute the task based on the command.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

Electromagnetic interference (“EMI”) is mitigated for portable magnetic resonance imaging (“MRI”) systems using postprocessing interference suppression techniques that make use of EMI detectors external to the MRI system imaging volume to detect EMI signals and remove them from acquired magnetic resonance data. EMI correction models, including static transfer function-based models, dynamic transfer function-based models, correction weight-based models, or parallel imaging kernel-based models can be used to remove the EMI-related artifacts from the magnetic resonance data.

IPC Classes  ?

• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G01R 33/422 - Screening of the radiofrequency field

Abstract

Disclosed are bispecific compounds (degraders) that target tau protein for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat neurodegenerative and neuropsychiatric diseases associated with aberrant tau.

IPC Classes  ?

• C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 487/04 - Ortho-condensed systems

Abstract

A single-sided magnet and magnetic resonance imaging (“MRI”) system are portable and lightweight, enabling use as a point-of care (“POC”) MRI device. The portable MRI system includes a magnet assembly containing layers of magnet blocks, such as rare-earth magnet blocks. The magnet blocks are arranged in concentric rings in each layer, and surround a central aperture extending through the magnet assembly. The central aperture is sized to allow a medical instrument, such as a needle, to pass through the central aperture. The portable MRI system can therefore be used for image guidance in lumbar puncture (“LP”) and other medical procedures.

IPC Classes  ?

• A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• G01R 33/383 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using permanent magnets
• G01R 33/38 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field
• G01R 33/385 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using gradient magnetic field coils
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

Methods and apparatus are provided for affecting an appearance of skin by harvesting small portions of tissue from a donor (first) site and applying them at a recipient (second) site. A plurality of micrografts can be formed from a piece of graft tissue and attached to a dressing material. The dressing material can then be expanded to increase a separation distance between the micrografts, and the dressing material having spaced-apart micrografts attached thereto can be applied to a prepared recipient site. An apparatus can be provided that expands the dressing material using a pressurized fluid. A further method can include providing a suspension of small portions of graft tissue in a solution. The solution can be injected into blisters formed at a recipient (second) site and the tissue portions allowed to attach and proliferate. A method and apparatus can also be provided for forming corresponding blisters at a donor site and at a recipient site. The raised (removed) portions of the blisters can be removed and attached to a dressing material, and the portions from the donor (first) site can be placed onto the exposed blister areas at the recipient site.

IPC Classes  ?

• A61B 17/322 - Skin grafting apparatus
• A61F 2/10 - Hair or skin implants
• A61B 17/00 - Surgical instruments, devices or methods, e.g. tourniquets

Abstract

Systems and methods are provided for semi-automated, portable, ultrasound guided cannulation. The systems and methods provide for image analysis to provide for segmentation of vessels of interest from image data. The image analysis provides for guidance for insertion of a cannulation system into a subject which may be accomplished by a non-expert based upon the guidance provided. The guidance may include an indicator or a mechanical guide to guide a user for inserting the vascular cannulation system into a subject to penetrate the vessel of interest.

IPC Classes  ?

• A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
• A61B 8/12 - Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters

Abstract

Provided herein are compounds useful as imaging agents. Exemplary compounds provided herein are useful as myeloperoxidase imaging agents using magnetic resonance or nuclear imaging techniques. Methods for preparing the compounds provided herein and diagnostic methods using the compounds are also provided.

IPC Classes  ?

• C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic System

Abstract

In some embodiments, systems, methods, and media for capsule-based multimode endoscopy are provided. In some embodiments, a probe for capsule-based multimode endoscopy is provided, the probe comprising: a rigid capsule; a flexible tether coupled to a proximal end of the capsule; a rotatable reflective surface disposed within the capsule; a static ball lens disposed within the capsule; a first optical fiber optically coupled to the ball lens, the first optical fiber passing through the flexible tether; a second optical fiber optically coupled to the ball lens, the second optical fiber passing through the flexible tether; a graded index fiber disposed between a distal end of the second optical fiber and the ball lens, the graded index fiber optically coupled to the second optical fiber and the ball lens.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
• A61B 1/01 - Guiding arrangements therefor
• A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
• A61B 1/07 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with illuminating arrangements using light-conductive means, e.g. optical fibres

Abstract

Systems, methods, and devices are described herein for detecting and/or monitoring target extracellular vesicles (“EVs”), e.g., to detect and/or monitor cancer treatment, such as breast cancer, in a subject. The methods can include obtaining a nano-plasmonic array including nanostructures configured to amplify one or more specific wavelengths of electromagnetic radiation, flowing a liquid sample over the nano-plasmonic array, optionally labeling target EVs captured on the nano-plasmonic array with one or more reporter groups, projecting electromagnetic radiation onto the labeled target EVs captured on the nano-plasmonic array, and capturing an image of the target EVs by receiving electromagnetic radiation emitted, scattered, or reflected by the labeled target EVs or by reporter groups on the labeled target EVs.

IPC Classes  ?

• G01N 21/552 - Attenuated total reflection
• G01N 15/02 - Investigating particle size or size distribution
• G01N 15/14 - Electro-optical investigation
• G01N 21/64 - Fluorescence; Phosphorescence
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

Systems and methods are provided for a deep learning-based digital breast tomosynthesis (DBT) image reconstruction that mitigates limited angular artifacts and improves in-depth resolution of the resulting images. The systems and methods may reduce the sparse-view artifacts in DBT via deep learning without losing image sharpness and contrast. A deep neural network may be trained in a way to reduce training-time computational cost. An ROI loss method may be used for further improvement on the resolution and contrast of the images.

IPC Classes  ?

• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
• A61B 6/02 - Devices for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis

Abstract

Systems and methods of optical transcutaneous oxygenation monitoring. The oxygenation monitor comprises a photoluminescent oxygen-sensitive probe, a photon source positioned to direct photons at the probe, a photodetector positioned to detect light emitted from the probe when the photon source directs photons at the probe, a controller in electrical communication with the photon source and the photodetector, the controller being configured to execute a program stored in the controller to calculate a level of oxygen adjacent the probe from an electrical signal received from the photodetector. The photon source, the photodetector, and the controller are disposed in or on a support structure.

IPC Classes  ?

• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

Obtain covariates and an outcome data for a population. Partition the population into a plurality of subgroups. Produce outcomes predictions by applying a machine learning model to the covariate data for the population. Establish performance measures based on the outcomes predictions. Compare the performance measures for at least one subgroup to the performance measures for at least one other subgroup. Identify an outlying subgroup for which the machine learning model produces performance measures that are different than the performance measures for one or more other subgroups. Optionally, retrain the machine learning model on additional covariate and outcomes data for the outlying subgroup.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation

Abstract

The present disclosure compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the TEAD transcription factor, and are useful in the treatment of diseases related to the activity of TEAD transcription factor including, e.g., cancer and other diseases.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07C 229/58 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho- position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
• C07C 255/58 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
• C07C 211/56 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
• C07D 249/08 - 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
• C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• C07D 213/80 - Acids; Esters in position 3
• C07C 229/44 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
• C07C 211/55 - Diphenylamines
• C07D 215/227 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
• C07D 275/06 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
• C07C 229/48 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
• C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 239/42 - One nitrogen atom
• C07D 241/28 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
• C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
• C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 231/56 - Benzopyrazoles; Hydrogenated benzopyrazoles
• C07D 235/18 - Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
• C07D 317/32 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 233/61 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 209/08 - Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 295/135 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• C07C 237/40 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
• C07C 311/44 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring